Use of intravenous amrinone in the short-term management of refractory heart failure in pregnancy.
The use of amrinone, a cardiac inotropic agent with vasodilatory properties, has not been described in human pregnancy. We report the use of amrinone in a woman at 18 weeks' gestation who had congestive heart failure secondary to bacterial endocarditis. Although her cardiac output and congestive heart failure improved, she developed hypoxemia, metabolic acidosis, and premature ventricular contractions. These effects resolved when the amrinone treatment was stopped.
Jelsema
R D
RD
Department of Obstetrics and Gynecology, Hutzel Hospital/Wayne State University School of Medicine, Detroit, Michigan.
Bhatia
R K
RK
Ganguly
S
S
D000140:Acidosis, Lactic / Q000139:chemically induced; D000328:Adult; D000676:Amrinone / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004697:Endocarditis, Bacterial / Q000150:complications*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D000860:Hypoxia / Q000139:chemically induced; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D000676:Amrinone